Faralimomab
Faralimomab is a mouse monoclonal antibody and an immunomodulator.[1]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | Interferon receptor |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
 N Y (what is this?) (verify) | |
References
- "WHO Drug Information" (PDF). Archived from the original (PDF) on 2011-06-04. Retrieved 2009-09-24.
| Intracellular (initiation) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Chemokine |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CSF |
| ||||||||||||
| Interferon |
| ||||||||||||
| Interleukin |
| ||||||||||||
| TGFβ |
| ||||||||||||
| TNF |
| ||||||||||||
| Others |
| ||||||||||||
| |||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.